Swiss approve reimbursement for Mallinckrodt treatment
Mallinckrodt PLC said Tuesday that Swiss regulators have approved for reimbursement a treatment for patients who develop certain complications following lung transplants, including the pharmaceutical company's Therakos Cellex photopheresis system.
Switzerland's Federal Department of Home Affairs has approved reimbursement of extracorporeal photopheresis (ECP) treatment ' during which blood cells are treated outside the body and returned to the bloodstream ' for patients there with bronchiolitis...